Barclays Sticks to Their Hold Rating for Icon (ICLR)
Barclays analyst Luke Sergott maintained a Hold rating on Icon today and set a price target of $200.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Sergott is an analyst with an average return of -2.1% and a 42.02% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Illumina, Exact Sciences, and Mettler-Toledo.
In addition to Barclays, Icon also received a Hold from BMO Capital’s Sean Dodge in a report issued on December 4. However, on December 8, Truist Financial maintained a Buy rating on Icon (NASDAQ: ICLR).
Based on Icon’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.04 billion and a net profit of $2.36 million. In comparison, last year the company earned a revenue of $2.03 billion and had a net profit of $197.13 million
Read More on ICLR:
Disclaimer & DisclosureReport an Issue
- Jefferies says market thinking ‘backwards’ on FDA one trial proposal
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Icon’s Hold Rating: Navigating Leadership Transition and Customer Challenges Amid Market Recovery
- Icon initiated with a Market Perform at BMO Capital
